Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inspira Technologies Oxy BHN ( (IINN) ) has provided an announcement.
On January 21, 2026, Inspira Technologies announced that two previously disclosed binding purchase orders worth $22.5 million and $27 million, first reported on July 2 and August 19, 2025, have progressed to the final budgetary validation and fund allocation stage within relevant governmental procurement processes. Approximately 91% of the combined orders has passed commercial and administrative review and is now awaiting final budgetary authorization, the last administrative hurdle before fund release and operational execution, with payment and revenue from these contracts expected over the 2026 fiscal cycle as governmental budget approvals and deployment milestones are completed; the company says it has finished internal preparations and remains focused on converting this contracted backlog into delivered systems and recognized revenue, underscoring the potential for a meaningful boost to its 2026 operating performance and its positioning in international life-support procurement markets.
The most recent analyst rating on (IINN) stock is a Sell with a $0.84 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.
The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., and underpins development of the next-generation INSPIRA ART500 for awake, spontaneously breathing patients. The company is also developing HYLA, a proprietary continuous, non-invasive blood sensor platform, and positions itself as an emerging life-support and MedTech platform with multiple cleared products and a growing IP portfolio.
Average Trading Volume: 182,652
Technical Sentiment Signal: Strong Sell
Current Market Cap: $31.31M
Find detailed analytics on IINN stock on TipRanks’ Stock Analysis page.